| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Zevra Therapeutics (NASDAQ:ZVRA) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:32 PM.
Here's what investors need to know about the announcement.
Zevra Therapeutics missed estimated earnings by -48.0%, reporting an EPS of $-0.4 versus an estimate of $-0.27.
Revenue was up $10.92 million from the same period last year.
Last quarter the company missed on EPS by $0.1 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Zevra Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.3 | -0.39 | -0.23 | -0.17 |
| EPS Actual | -0.4 | -0.15 | -0.34 | -0.26 |
| Revenue Estimate | 3.38M | 2.90M | 2.65M | 3.20M |
| Revenue Actual | 2.90M | 8.47M | 2.88M | 2.30M |
To track all earnings releases for Zevra Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ZVRA
